GlassScriptPhysician profile
Katherine Skillman
NPI 1245421072
$1,268.51
in general payments reported to CMS, 2019-2025
28 companies · $85.41 in 2025
The $85.41 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $348 · 2022: $412 · 2023: $286 · 2024: $137 · 2025: $85.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $183.12 | 2021-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $150.12 | 2021-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $108.75 | 2021-2024 | Shingrix |
| Abbott Laboratories | $91.83 | 2021-2023 | Freestyle Libre 2 |
| Novo Nordisk INC | $83.89 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.72 | 2022-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $67.60 | 2021-2024 | |
| Astellas Pharma US INC | $54.28 | 2021-2025 | Veozah |
| Merck Sharp & Dohme LLC | $46.58 | 2022-2023 | Verquvo, Belsomra, Vaxneuvance |
| Biohaven Pharmaceuticals, INC. | $41.49 | 2021 | |
| Abbvie INC. | $31.37 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $30.27 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $30.12 | 2022-2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $28.33 | 2023 | Farxiga, Flumist Quadrivalent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.75 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $22.95 | 2025 | Tonmya |
| Supernus Pharmaceuticals, INC. | $20.33 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.28 | 2025 | Rexulti |
| Mylan Specialty L.P. | $19.51 | 2023 | Yupelri |
| Medtronic, INC. | $19.11 | 2023 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $18.11 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.63 | 2022 | |
| Hologic Sales and Service, LLC | $17.33 | 2023 | Acessa Provu System |
| Takeda Pharmaceuticals U.S.A., INC. | $15.39 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.04 | 2021 | |
| Eisai INC. | $12.93 | 2021 | |
| Ironwood Pharmaceuticals, INC | $11.65 | 2021 | |
| Genentech USA, INC. | $5.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Skillman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.